Favorable Court Decision and Market Potential Propel Liquidia Technologies’ Buy Rating

Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of $25.00.

Serge Belanger’s rating is based on the recent developments surrounding Liquidia Technologies, particularly the favorable court decision that clears the way for FDA approval of Yutrepia. The dismissal of cross-claims by United Therapeutics against the FDA has removed legal obstacles, paving a clear path for the approval process to proceed smoothly.
Additionally, the upcoming presentations at the American Thoracic Society meeting, where Liquidia will showcase results from the ASCENT trial, are expected to highlight Yutrepia’s unique benefits. These factors, combined with the potential commercial launch in a growing market valued at approximately $2 billion, support the Buy rating and the $25 price target set by Belanger.

In another report released on May 5, Scotiabank also maintained a Buy rating on the stock with a $36.00 price target.